Products Categories
CAS No.: | 60607-34-3 |
---|---|
Name: | Oxatomide |
Article Data: | 2 |
Molecular Structure: | |
Formula: | C27H30N4O |
Molecular Weight: | 426.561 |
Synonyms: | Celtect;Cobiona;Dasten;KW 4354;NSC 309710;Oxatomide;R 35443;Tinset; |
EINECS: | 262-320-9 |
Density: | 1.175 g/cm3 |
Melting Point: | 153.60C |
Boiling Point: | 621.1 °C at 760 mmHg |
Flash Point: | 329.4 °C |
Solubility: | DMSO: soluble |
Appearance: | White powder |
Hazard Symbols: | Xi; Xn |
Risk Codes: | 22-36/37/38 |
Safety: | 26-36 |
Molecular Formula: C27H30N4O
Molecular Weight: 426.55
EINECS: 262-320-9
Density: 1.175 g/cm3
Flash Point: 329.4 °C
Melting Point: 153.6 °C
Appearance: White powder.
Enthalpy of Vaporization: 95.4 kJ/mol
Boiling Point: 621.1 °C at 760 mmHg
Vapour Pressure: 5.1E-16 mmHg at 25°C
Solubility: DMSO: soluble Insoluble in water
Stability of Oxatomide (60607-34-3): Stable at normal temperatures and pressures.
Synonyms: Oxatomide ; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2h-benzimidazol-2 ; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone ; 1,3-Dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-2h-benzimidazol-2-on ; 2H-benzimidazol-2-one,1,3-Dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propy ; KW-4354 ; Oxatimide
Product Categories: Intermediates & Fine Chemicals ; Pharmaceuticals
Following is the molecular structure of Oxatomide (60607-34-3):
Usage of Oxatomide (60607-34-3): Orally active anti-allergic agent; related structurally to cinnarizine and having a novel biphasic mode of action
Safety Information of Oxatomide (60607-34-3):
Hazard Codes: Xn,Xi
Xi: Irritant Xn: Harmful
Risk Statements: 22-36/37/38
22: Harmful if swallowed
36/37/38: Irritating to eyes, respiratory system and skin
Safety Statements: 26-36
26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 36: Wear suitable protective clothing
WGK Germany: 3
RTECS: DE2276000
1. | orl-rat LD50:1410 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
2. | ipr-rat LD50:63 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
3. | ivn-rat LD50:29 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
4. | orl-mus LD50:9596 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
5. | ipr-mus LD50:7926 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
6. | ivn-mus LD50:25 mg/kg | YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. 12 (1984),2769. | ||
7. | orl-gpg LD50:320 mg/kg | DRFUD4 Drugs of the Future. 3 (1978),465. | ||
8. | ivn-gpg LD50:23 mg/kg | DRFUD4 Drugs of the Future. 3 (1978),465. |
Poison by ingestion, intraperitoneal, and intravenous routes. An experimental teratogen. Experimental reproductive effects. Used to treat allergies and asthma. When heated to decomposition it emits toxic fumes of NOx.